Characterization of host immune responses in Ebola virus infections

References

• Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011;204(Suppl 3):S785-90
   PubMed Web of Science ®Google Scholar
• Reed DS, Lackemeyer MG, Garza NL, et al. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 2011;13(11):930-6
   PubMedGoogle Scholar
• Weingartl HM, Embury-Hyatt C, Nfon C, et al. Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2012;2:811
   PubMed Web of Science ®Google Scholar
• Kobinger GP, Leung A, Neufeld J, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 2011;204(2):200-8
   PubMed Web of Science ®Google Scholar
• Marsh GA, Haining J, Robinson R, et al. Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 2011;204(Suppl 3):S804-9
   PubMedGoogle Scholar
• Nkoghe D, Leroy EM, Toung-Mve M, Gonzalez JP. Cutaneous manifestations of filovirus infections. Int J Dermatol 2012;51(9):1037-43
   PubMed Web of Science ®Google Scholar
• Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley P, editors. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2013
   Google Scholar
• Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol 2007;8(11):1159-64
   PubMed Web of Science ®Google Scholar
• Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011;377(9768):849-62
   PubMed Web of Science ®Google Scholar
• Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999;179(Suppl 1):S28-35
   PubMed Web of Science ®Google Scholar
• Rodriguez LL, De Roo A, Guimard Y, et al.Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1995;179(Suppl 1):S170-6
   Google Scholar
• Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004;6(20):1-24
   Google Scholar
• Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005;37(8):1560-6
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188(11):1618-29
   PubMed Web of Science ®Google Scholar
• Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003;188(11):1630-8
   PubMed Web of Science ®Google Scholar
• Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003;170(6):2797-801
   PubMed Web of Science ®Google Scholar
• Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002;80(3):169-79
   PubMed Web of Science ®Google Scholar
• Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999;235:97-116
   PubMed Web of Science ®Google Scholar
• Ebola haemorrhagic fever in Zaire. 1976. Bull World Health Organ 1978;56(2):271-93
   Google Scholar
• Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006;80(6):3009-20
   PubMed Web of Science ®Google Scholar
• Reid SP, Leung LW, Hartman AL, et al.Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006;80(11):5156-67
   PubMed Web of Science ®Google Scholar
• Reid SP, Valmas C, Martinez O, et al. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007;81(24):13469-77
   Google Scholar
• Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003;77(14):7945-56
   PubMed Web of Science ®Google Scholar
• Chang TH, Kubota T, Matsuoka M, et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009;5(6):e1000493
   PubMed Web of Science ®Google Scholar
• Cardenas WB, Loo YM, Gale M Jr, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006;80(11):5168-78
   PubMed Web of Science ®Google Scholar
• Kimberlin CR, Bornholdt ZA, Li S, et al. Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci USA 2010;107(1):314-19
   Google Scholar
• Leung DW, Prins KC, Borek DM, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 2010;17(2):165-72
   PubMed Web of Science ®Google Scholar
• Kuhl A, Pohlmann S. How Ebola virus counters the interferon system. Zoonoses Public Health 2012;59(Suppl 2):116-31
   Google Scholar
• Schumann M, Gantke T, Muhlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol 2009;83(17):8993-7
   PubMed Web of Science ®Google Scholar
• Jin H, Yan Z, Prabhakar BS, et al. The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J Gen Virol 2010;91(Pt 2):352-61
   Google Scholar
• Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001;82(Pt 6):1365-73
   PubMed Web of Science ®Google Scholar
• Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009;106(8):2886-91
   PubMed Web of Science ®Google Scholar
• Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog 2013;9(5):e1003258
   PubMed Web of Science ®Google Scholar
• Ou W, Delisle J, Jacques J, et al. Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J 2012;9:32
   Google Scholar
• Francica JR, Varela-Rohena A, Medvec A, et al. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog 2010;6(9):e1001098
   PubMed Web of Science ®Google Scholar
• Noyori O, Matsuno K, Kajihara M, et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses. Virology 2013;446(1-2):152-61
   Google Scholar
• Groseth A, Marzi A, Hoenen T, et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 2012;8(8):e1002847
   Google Scholar
• Mehedi M, Falzarano D, Seebach J, et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 2011;85(11):5406-14
   PubMed Web of Science ®Google Scholar
• Mohan GS, Li W, Ye L, et al. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 2012;8(12):e1003065
   PubMed Web of Science ®Google Scholar
• Mahanty S, Gupta M, Paragas J, et al. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 2003;312(2):415-24
   Google Scholar
• Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002;55(1):151-9
   PubMed Web of Science ®Google Scholar
• Gibb TR, Bray M, Geisbert TW, et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 2001;125(4):233-42
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Gibb TR, et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000;80(2):171-86
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5(4):423-6
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000;5(1):5-7
   Google Scholar
• Wauquier N, Becquart P, Padilla C, et al. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4:10
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128(1):163-8
   PubMed Web of Science ®Google Scholar
• Hutchinson KL, Rollin PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis 2007;196(Suppl 2):S357-63
   PubMedGoogle Scholar
• Gupta M, MacNeil A, Reed ZD, et al. Serology and cytokine profiles in patients infected with the newly discovered Bundibugyo ebolavirus. Virology 2012;423(2):119-24
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008;82(11):5664-8
   PubMed Web of Science ®Google Scholar
• Warfield KL, Perkins JG, Swenson DL, et al. Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004;200(2):169-79
   PubMed Web of Science ®Google Scholar
• Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97(6):2731-6
   Google Scholar
• Gupta M, Mahanty S, Bray M, et al. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J Virol 2001;75(10):4649-54
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007;196(Suppl 2):S404-12
   PubMedGoogle Scholar
• Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11(7):786-90
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007;81(12):6379-88
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007;196(Suppl 2):S430-7
   PubMed Web of Science ®Google Scholar
• Gupta M, Mahanty S, Greer P, et al. Persistent infection with Ebola virus under conditions of partial immunity. J Virol 2004;78(2):958-67
   PubMed Web of Science ®Google Scholar
• Olinger GG, Bailey MA, Dye JM, et al. Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005;79(22):14189-96
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Hensley L, Asiedu C, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011;17(9):1128-31
   PubMed Web of Science ®Google Scholar
• Gaufin T, Ribeiro RM, Gautam R, et al. Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication. Retrovirology 2010;7:42
   Google Scholar
• Van Rompay KK, Blackwood EJ, Landucci G, et al. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J 2006;3:22
   Google Scholar
• Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005;175(2):1184-91
   PubMed Web of Science ®Google Scholar
• Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001;286(2):384-90
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75(6):2660-4
   PubMed Web of Science ®Google Scholar
• Rao M, Bray M, Alving CR, et al. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002;76(18):9176-85
   PubMed Web of Science ®Google Scholar
• Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998;4(1):37-42
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998;246(1):134-44
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012;109(13):5034-9
   PubMed Web of Science ®Google Scholar
• Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009;4(4):e5308
   PubMed Web of Science ®Google Scholar
• Wong G, Richardson JS, Pillet S, et al. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 2012;4(158):158ra146
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013;110(5):1893-8
   PubMed Web of Science ®Google Scholar
• Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 2012;7(4):e36192
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012;4(138; 138ra181
   Web of Science ®Google Scholar
• Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 2012;109(44):18030-5
   PubMed Web of Science ®Google Scholar
• Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355(9222):2210-15
   PubMed Web of Science ®Google Scholar
• Leroy EM, Baize S, Debre P, et al. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001;124(3):453-60
   PubMed Web of Science ®Google Scholar
• Becquart P, Wauquier N, Mahlakoiv T, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010;5(2):e9126
   PubMedGoogle Scholar
• Nkoghe D, Padilla C, Becquart P, et al. Risk factors for Zaire ebolavirus--specific IgG in rural Gabonese populations. J Infect Dis 2011;204(Suppl 3):S768-75
   Google Scholar
• Qiu X, Audet J, Wong G, et al. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep 2013;3:3365
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit. Democratic Republic of the Congo 1995;J Infect Dis 1999;179(Suppl 1):S177-87
   Google Scholar
• Ksiazek TG, West CP, Rollin PE, et al.A for the detection of antibodies to Ebola viruses. J Infect Dis 1999;179(Suppl 1):S192-8
   PubMed Web of Science ®Google Scholar
• Wauquier N, Becquart P, Gasquet C, Leroy EM. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis 2009;15(7):1136-7
   PubMed Web of Science ®Google Scholar
• Sobarzo A, Ochayon DE, Lutwama JJ, et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013;369(5):492-3
   PubMed Web of Science ®Google Scholar
• Sobarzo A, Groseth A, Dolnik O, et al. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu). J Infect Dis 2013;208(2):299-309
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207(10):2053-63
   PubMed Web of Science ®Google Scholar
• Prchal M, Pilz A, Simma O, et al. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity. Vaccine 2009;27(Suppl 6):G17-20
   Google Scholar
• Smith LM, Hensley LE, Geisbert TW, et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis 2013;208(2):310-18
   PubMed Web of Science ®Google Scholar
• Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009;2(1-2):12-17
   PubMed Web of Science ®Google Scholar
• Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010;6(5):e1000904
   PubMed Web of Science ®Google Scholar
• Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999;6(9):1574-83
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Fernando L, et al. mAbs and Ad-Vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013;5(207):207ra143
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Experimental Vaccine for Prevention of Ebola Virus Infection 2014. Available from: http://clinicaltrials.gov/ct/show/NCT00374309
   Google Scholar
• ClinicalTrials.gov. Experimental Ebola Vaccine Trial 2014. Available from: http://clinicaltrials.gov/show/NCT00072605
   Google Scholar
• ClinicalTrials.gov. Ebola and Marburg Virus Vaccines. (2014). Available from: http://clinicaltrials.gov/ct2/show/NCT00605514
   Google Scholar
• ClinicalTrials.gov. Evaluating an Ebola and a Marburg Vaccine in Uganda. (2014). Available from http://clinicaltrials.gov/ct2/show/NCT00997607
   Google Scholar